An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
Explore this paper's citation graph
Summary
Similar drug exposures and safety profiles were observed in patients receiving panitumumab 6 mg/kg every 2 weeks with either 30- or 60-minute infusions and antitumor activity was seen in some patients.
- Type
- book
- Published
- 2009-01-01
- Cited by
- 45
- References
- 15
- Access
- Open access
- OpenAlex
- https://openalex.org/W19203894
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24517067
Keywords
Art, Philosophy
References
- Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
- The EGF receptor - an essential regulator of multiple epidermal functions.
- Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
- Fully Human Therapeutic Monoclonal Antibodies
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
- Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
- Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
- New guidelines to evaluate the response to treatment in solid tumors
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
- High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
- Pharmacology of epidermal growth factor inhibitors.
- Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.
Cited by
- Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review.
- Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
- Le panitumumab (Vectibix®) en oncologie digestive: quel rationnel pharmacologique et pharmacocinétique ?
- Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
- Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab
- Panitumumab: a summary of clinical development in colorectal cancer and future directions.
- On biomarkers and pathways in rectal cancer: What's the target?
- Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
- Metastatic Colorectal Cancer: Focus on Panitumumab
- Panitumumab
- Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
- Panitumumab in metastatic colorectal cancer
- Panitumumab for the treatment of metastatic colorectal cancer: a review.
- Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.
- Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report
- CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
- Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
- Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer.
- Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
- Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
Related papers
No related papers recorded.